0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Prolonging Tamoxifen Therapy for Primary Breast Cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project Clinical Trial

BERNARD FISHER, M.D.; ANN BROWN, ScD.; NORMAN WOLMARK, M.D.; CAROL REDMOND, ScD.; D. LAWRENCE WICKERHAM, M.D.; JAMES WITTLIFF, Ph.D.; NIKOLAY DIMITROV, M.D.; SANDRA LEGAULT-POISSON, M.D.; HARVEY SCHIPPER, M.D.; and DAVID PRAGER, M.D.
[+] Article and Author Information

▸Requests for reprints should be addressed to Bernard Fisher, M.D.; NSABP Headquarters, Room 914 Scaife Hall, 3550 Terrace Street; Pittsburgh, PA 15261.


NSABP INVESTIGATORS; Pittsburgh and Allentown, Pennsylvania; Louisville, Kentucky; East Lansing, Michigan; and Montreal, Quebec, and Winnipeg, Manitoba, Canada


©1987 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1987;106(5):649-654. doi:10.7326/0003-4819-106-5-649
Text Size: A A A

Objective: To determine whether prolonging the duration of tamoxifen administration beyond the cessation of a combined chemotherapy regimen benefits patients with primary breast cancer with positive findings in axillary nodes who benefit initially from the combined regimen.

Design: Nonrandomized, nonconcurrent cohort study.

Setting: National Surgical Adjuvant Breast and Bowel Project, conducted in 68 institutions in North America.

Patients: Women were included if they had breast cancer with positive nodes and were aged 49 years or less with both estrogen and progesterone receptor levels of 10 fmol or more, aged 50 to 59 years with progesterone receptor levels of 10 fmol or more, or aged 60 to 69 years. Two cohorts were compared: patients who were randomly assigned to the tamoxifen arm of the adjuvant chemotherapy trial (randomized patients) and women who were added to this arm after randomization had ceased (registered patients). Three hundred seventy-seven women in each group who were disease free at the end of the initial 2-year treatment period were followed for an additional 3 years.

Interventions: All received melphalan, fluorouracil, and tamoxifen (10 mg twice daily by mouth) for 2 years. Registered patients (but not randomized patients) were offered tamoxifen for a third year after the initial 2-year treatment period, and 273 (72%) agreed.

Measurements and Main Results: Women receiving a third year of tamoxifen had a better disease-free survival rate (odds ratio, 1.54; 95% confidence interval, 1.14 to 2.07; p = 0.004) and survival rate (odds ratio, 1.56; 95% Cl, 1.02 to 2.37; p = 0.04) through their fifth postoperative year. Women aged 50 years or more benefited, but those aged 49 years or less did not.

Conclusions: The benefit of tamoxifen given to tamoxifen-responsive patients in conjunction with melphalan and fluorouracil appears to be enhanced when the tamoxifen treatment is continued beyond cessation of treatment with these agents.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)